Elanco Animal Health Incorporated (ELAN) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt and Lease Obligation, CurrentUSD $73.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $3.85B.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt and Lease Obligation, CurrentUSD $73.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $3.92B.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt and Lease Obligation, CurrentUSD $74.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $3.94B.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD (m).
Elanco Animal Health Incorporated Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt and Lease Obligation, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt and Lease Obligation USD | Long-term Debt USD | Long-term Debt and Lease Obligation, Including Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-term Debt, Gross USD | Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Unused Borrowing Capacity, Fee USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $73.00M | (m) | $3.85B | $3.66B | $3.92B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 80.00% | (m) | (m) | (m) |
| 2026-03-31 | (m) | $73.00M | (m) | $3.92B | $3.74B | $3.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 80.00% | (m) | (m) | (m) |
| 2025-12-31 | (m) | $74.00M | (m) | $3.94B | $3.76B | $4.02B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $63.00M | $63.00M | $1.24B | $548.00M | $20.00M | $1.86B | $3.79B | 80.00% | $28.00M | (m) | (m) |
| 2025-09-30 | (m) | $62.00M | (m) | $3.96B | $3.77B | $4.02B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 80.00% | (m) | (m) | (m) |
| 2025-06-30 | (m) | $61.00M | (m) | $4.15B | $3.95B | $4.21B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 89.00% | (m) | (m) | (m) |
| 2025-03-31 | $44.00M | (m) | $4.35B | (m) | $4.39B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 80.00% | (m) | (m) | (m) |
| 2024-12-31 | (m) | $44.00M | (m) | $4.28B | $4.32B | $4.32B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $44.00M | (m) | $4.28B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $54.00M | $154.00M | $2.52B | $1.11B | $180.00M | $332.00M | $4.35B | 82.00% | $28.00M | (m) | (m) |
| 2024-09-30 | $44.00M | (m) | $4.31B | (m) | $4.36B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 81.00% | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | $4.32B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $213.00M | (m) | $5.46B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $38.00M | (m) | $5.73B | (m) | $5.76B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 78.00% | (m) | (m) | (m) |
| 2023-12-31 | $38.00M | (m) | $5.74B | (m) | $5.77B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | $425.00M | $175.00M | $3.72B | $1.22B | $235.00M | $5.82B | 78.00% | $50.00M | (m) | (m) |
| 2023-09-30 | $39.00M | (m) | $5.87B | (m) | $5.91B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 76.00% | (m) | (m) | (m) |
| 2023-06-30 | $39.00M | (m) | $6.02B | (m) | $6.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $381.00M | (m) | $5.64B | (m) | $6.02B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $388.00M | (m) | $5.45B | (m) | $5.84B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $401.00M | $50.00M | $225.00M | $50.00M | $3.72B | $1.46B | $5.90B | (m) | $64.00M | (m) | (m) |
| 2022-09-30 | $394.00M | (m) | $5.51B | (m) | $5.90B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $56.00M | (m) | $6.01B | (m) | $6.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $61.00M | (m) | $6.07B | (m) | $6.13B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $294.00M | (m) | $6.03B | (m) | $6.32B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $308.00M | $805.00M | $48.00M | $135.00M | $48.00M | $5.06B | $6.40B | (m) | $82.00M | (m) | (m) |
| 2021-09-30 | $61.00M | (m) | $6.27B | (m) | $6.33B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $555.00M | (m) | $5.54B | (m) | $6.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $605.00M | (m) | $5.56B | (m) | $6.16B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $555.00M | (m) | $5.57B | (m) | $6.13B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $568.90M | $69.60M | $799.60M | $42.80M | $39.90M | $4.70B | $6.22B | (m) | $97.20M | (m) | (m) |
| 2020-09-30 | $553.60M | (m) | $5.59B | (m) | $6.14B | (m) | $567.60M | $68.00M | $797.50M | $40.30M | $39.90M | $4.71B | $6.24B | (m) | $101.10M | $16.80M | (m) |
| 2020-08-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.80M |
| 2020-06-30 | $25.90M | (m) | $2.03B | (m) | $2.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $26.00M | (m) | $2.04B | (m) | $2.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $24.50M | (m) | $2.33B | (m) | $2.35B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $24.50M | (m) | $2.34B | (m) | $2.36B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $27.10M | (m) | $2.38B | (m) | $2.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $29.00M | (m) | $2.44B | (m) | $2.47B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $29.00M | (m) | $2.44B | (m) | $2.47B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $0.00 | (m) | $2.48B | (m) | $2.48B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |